Table 2.
Pathology findings according to central review (n = 55)
| n (%) | |
|---|---|
| Grading | |
| G2 | 27 (49.1) |
| G3 | 6 (10.9) |
| No tumor | 19 (34.5) |
| Not evaluable | 2 (3.6) |
| Not applicablea | 1 (1.8) |
| Pathological T stage | |
| ypT0 | 21 (38.2) |
| ypT1 | 4 (7.3) |
| ypT2 | 15 (27.3) |
| ypT3 | 13 (23.6) |
| ypT4 | 1 (1.8) |
| Not applicablea | 1 (1.8) |
| Pathological N stageb | |
| ypN0 | 46 (83.6) |
| ypN1 | 6 (10.9) |
| ypN2 | 2 (3.6) |
| Not applicablea | 1 (1.8) |
| Total resected nodesb | |
| Median [IQ-IIIQ] | 15.5 [11-19] |
| Min-max | 0-34 |
| Not applicablea | 1 |
| Distal and proximal marginsb | |
| R0 | 53 (96.4) |
| R1 | 1 (1.8) |
| Not applicablea | 1 (1.8) |
| Circumferential resection margins | |
| Positive (≤1 mm) | 2 (3.6) |
| Negative (>1 mm) | 52 (94.5) |
| Not applicablea | 1 (1.8) |
| Pathological complete response rate (ypT0N0) | |
| Yes | 19 (34.5) |
| No | 36 (65.5) |
| TRG | |
| 0 | 19 (34.5) |
| 1 | 14 (25.5) |
| 2 | 16 (29.1) |
| 3 | 5 (9.1) |
| Not applicablea | 1 (1.8) |
Percentages may not equal 100 due to rounding.
IQ, first quartile; IIIQ, third quartile; TRG, tumor regression grading.
a
One patient did not have surgery due to disease progression during the neoadjuvant treatment.
b
Parameters assessed by local review.